FUNDAMENTAL AND CLINICAL STUDIES OF T-1220 AGAINST COMPLICATED URINARY TRACT INFECTIONS

• Published in: CHEMOTHERAPY Vol. 25; no. 5; pp. 1369 - 1378
• Main Authors: MITA, TOSHIHIKO, OHBE, TOORU, ITO, NOBORU, SUGIMOTO, MASAYUKI, ISHIGAMI, JOJI
• Format: Journal Article
• Language: Japanese
• Published: Japanese Society of Chemotherapy 1977
• ISSN: 0009-3165; 1884-5894
• DOI: 10.11250/chemotherapy1953.25.1369

1) Blood level The peak of blood levels in 3 healthy adult volunteers after single muscular injection at the dose of 1 g of T-1220 was observed at 30 min after Injection and the average concentration was 29.8 p, g/ml, showing 2.2 μg/ml even at 6 hr after injection. 2) Excretion rate in urine The average excretion rate within 6 hr after muscular injection in the same cases that the blood levels were measured was 63.5%. 3) Antibacterial activity The minimal inhibitory concentrations (MIC) of T-1220 against 100 strains of E. coli isolated from urinary tract infections were distributed in the range of 1.56-≥100 μg/ ml and the peak was.≥.100 μg/ml as same as in ABPC. Among 22 strains of Proteus group MIC to 20 strains was ≥200 μg/ml and MIC in each 1 strain were 6.25 and 25 μg/ml, respectively. The peak of MIC against 97 strains of Pseudomonas aeruginosa was distributed in the range of 6.25-25 μg/ml, showing that the antibacterial activity of T-1220 against Pseudomonas was 4-8 times superior to that of CBPC. The peak of MIC against 82 strains of Serratia marcescens widely distributed to 1.56-≥100 μg/ml and among them MIC to 73 strains were ≥100 μg/ml. 4) Clinical evaluation The results in 16 cases of complicated urinary tract infections showed that remarkably effective case (excellent) was 1, effective cases (good) 7, ineffective cases 8 and the effective rate was 50.0%. 5) Side effect In 1 out of 16 cases temporary rise of GOT and GPT was observed and any other abnormality was not observed, except 1 case complaining of cough.